세계의 전임상 이미징 시장(2023-2030년)

Title: Global Preclinical Imaging Market Size, Share & Trends Analysis Report by Product (MicroCT (Micro Computed Tomography), MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography), Ultrasound Imaging, Optical Imaging, Photoacoustic Imaging, and Others), by Application (Pharma and Biotech Companies, Research and Development, Neurology and Neuroscience, and Others), and by End-User (Pharma and Biotech Companies, Academic and Research Institutions, Hospitals and Medical Centers, Government Research Agencies, and Others)Forecast Period (2023-2030).

The global preclinical imaging market is anticipated to grow at a CAGR of 6.82% during the Forecast Period (2023-2030). The market's growth is attributed to enhancement of sensitivity and resolution. High-field MRI systems improve the sensitivity and resolution of scans, enabling researchers to detect and analyze delicate structural and functional modifications in animal models. This higher level of sensitivity and resolution is important for accurately modeling diseases and evaluating potential drug candidates. Accordingly market players are coming up with new products to cater the demand for new MRI devices. For instance, in May 2022,Bruker launched innovative magnetic resonance imaging (MRI) devices, including 7.4 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets, form a component of its product line of market-leading preclinical MRI systems. The BioSpec Maxwell 3 Tesla model was an enormous success, and the Liquid is ceased to essential owing to a new generation of Maxwell 7.4 Tesla and 9.4 Tesla magnets. while providing high-field sensitivity and nitrogen or helium refills resolution for innovative PET/MR and MRI preclinical research.

Segmental Outlook

The global preclinical imaging market is segmented on the product, application, and end-user. Based on the product, the market is sub-segmented into MicroCT, MRI, PET, ultrasound imaging, optical imaging, photoacoustic imaging, and others. Based on the application, the market is sub-segmented into pharma and biotech companies, research and development, neurology and neuroscience, and others. Furthermore, on the basis of end-user, the market is sub-segmented into pharma and biotech companies, academic and research institutions, hospitals and medical centers, government research agencies, and others. The pharma and biotech company's subcategory is expected to capture a significant portion of the market share within the end-user segment. This is attributed to the development and reemergence of infectious diseases, the demand for preclinical imaging for enhanced comprehension of pathogens and encourage the creation of innovative therapies and vaccines.

The Ultrasound Imaging Sub-Segment is Anticipated to Hold a Considerable Share of the Global Preclinical Imaging Market

Among the product, the ultrasound imaging sub-segment is expected to hold a considerable share of the global preclinical imaging market. The segmental growth is attributed to the innovation in technology. Increased usage results from the ability of researchers to explore new preclinical research directions owing to advancements in imaging technologies such as ultrasound and photoacoustic imaging. Accordingly market players are coming up with new products to cater the demand for ultrasound and photoacoustic imaging system designed for preclinical use. For instance, in May 2022,FUJIFILM VisualSonics Inc., launched Vevo F2, the globe's first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 produces entire new signal pipeline, from transducer to display screen, and includes HD image processing technologies. In combination with multi-line processing, it improves image clarity and results in significantly higher frame rates than platforms from preceding generations.

Regional Outlook

The global preclinical imaging market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, as the region has grown increasingly desirable for preclinical research studies owing to increased government support for the growth of the research and development sector in the individual countries.

The North America Region is Expected to Grow at a Significant CAGR in the Global Preclinical Imaging Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the expansion of healthcare in the region. Global demand for advanced imaging technologies, especially preclinical imaging, is anticipated to increase as healthcare services grow. According to the US Bureau of Labor Statistics, in September 2023, Radiologic and MRI technologists' total employment is anticipated to increase by 6% between 2022 and 2032, faster than the average for all occupations. Over the next ten years, there are anticipated to be, on average, 15,700 openings for radiologic and MRI technologists. The need to replace workers that change careers or leave the workforce owing to retirement is predicted to cause a large portion of the available openings.

Market Players Outlook

The major companies serving the global preclinical imaging market include: Bruker Corp., Euro-BioImaging ERIC, FUJIFILM Holdings Corp., IVIM Technology Corp., Mediso Kft. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2019, Bruker collaborated to develop the first 18 Tesla, 11 cm bore, preclinical ultra-high field (UHF) MRI machine constantly.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global preclinical imaging market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Advanced Molecular Vision, Inc
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Aspect Imaging Ltd.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. AXT PTY LTD.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Preclinical Imaging Market by Product
  • 4.1.1. MicroCT (Micro Computed Tomography)
  • 4.1.2. MRI (Magnetic Resonance Imaging)
  • 4.1.3. PET (Positron Emission Tomography)
  • 4.1.4. Ultrasound Imaging
  • 4.1.5. Optical Imaging
  • 4.1.6. Photoacoustic Imaging
  • 4.1.7. Others ( Radiopharmaceuticals and Tracers, and Infrared Imaging )
• 4.2. Global Preclinical Imaging Market by Application
  • 4.2.1. Research and Development
  • 4.2.2. Neurology and Neuroscience
  • 4.2.3. Others (Toxicology and Safety Assessment, Gene Therapy and Molecular Imaging, and Precision Medicine, and Personalized Therapies)
• 4.3. Global Preclinical Imaging Market by End-User
  • 4.3.1. Pharma and Biotech Companies
  • 4.3.2. Academic and Research Institutions
  • 4.3.3. Hospitals and Medical Centers
  • 4.3.4. Government Research Agencies
  • 4.3.5. Others (Pharmacology and Toxicology Laboratories, and Regulatory Bodies & Authorities)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Bruker Corp.
• 6.2. Euro-BioImaging ERIC
• 6.3. FUJIFILM Holdings Corp.
• 6.4. IVIM Technology Corp.
• 6.5. Mediso Kft.
• 6.6. MR Solutions Ltd.
• 6.7. Oxford Nanoimaging Ltd.
• 6.8. PerkinElmer AES
• 6.9. Photon Etc. Inc
• 6.10. Revvity, Inc.
• 6.11. Shanghai United Imaging Healthcare Co., LTD.